Have Monitor, Will Travel?
Having monitors at the site keeping the trial in check is comforting for many sponsors used to the typical six, eight or 10 week monitoring schedule in a typical pivotal clinical trial. However, a variety of factors are converging to make the possibility of remote or centralized monitoring a key part of any clinical trial. Those factors include adaptive trials, usage of remote monitoring in observational trials, cost pressures, and efficiencies.
Ramita Tandon, Senior Director, Project Management, Peri-approval Services (PACE), for Parexel will chair and present along with Michael J. Rosenberg, MD, President and CEO, Health Decisions Inc., at the DIA session “Centralized Monitoring: When Does It Make Sense?” on Monday June 14 from 3:30 to 5 p.m. for the Clinical Research and Development/Clinical Supplies track.
In her position at Parexel, Tandon told Applied Clinical Trials that sponsors do have concerns with the remote monitoring concept. Specifically, these are related to pivotal trials and Source Document Verification (SDV). To support and illustrate the remote monitoring strategy, Tandon will present a case study of a global Phase IIIb trial featuring key cardiovascular endpoints that were collected and submitted as part of the trial. “We’re going to walk attendees through this type of monitoring strategy,” said Tandon. She believes that the Phase IIIb study is an excellent model for sponsors to get comfortable with and then consider for earlier phase trials.
“There is hesitancy to use remote monitoring with the pivotal trials,” explains Tandon. However, by providing the Phase IIIb case study, and that example of endpoint studies used for submissions, balanced with the monitoring rigor required for data safety, she believes that confidence will follow.
In regard to the SDV issue, Tandon related: “Once sponsors decide to use the remote monitoring approach, the question to the CROs becomes how do you get to that percentage of SDVs?” Tandon says that the SDV percentages range from the very conservative to the opposite on observational programs. These issues will also be discussed at the session.
Remote monitoring is not an easy decision, but once made, Tandon says it can’t be implemented successfully without the optimal workflow processes, as well as a supportive infrastructure.
In addition, the speakers will discuss the best scenarios of remote monitoring, which take sponsors away from the mindset of traditional six, eight or 10-week monitoring visits. The flexible remote monitoring plan positively impacts the bottom line of budgets, and believe it or not, increases site satisfaction. And a happy site makes for a happy sponsor. Tandon said, “Practicing site management remotely becomes easier over the phone in the observational studies because you are observing physician practices. Also, prescribers love it because once they realize they are part of a clinical trial and it’s easy to do, they send positive feedback to the sponsors.”
Related Articles
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
